TRT long-term risks: what the evidence actually shows

What did @ali_on_t actually say?

The creator listed four long-term risks of TRT: infertility, blood thickening, blood clots, and poor cardiovascular health. Then came the reassurance: if you monitor your blood properly, work with a knowledgeable doctor, and take medications correctly, "you can avoid these side effects." That's a short video making a big promise. Let's see how much of it holds up.

To be fair, the framing is generally responsible. Naming real risks, pointing people toward physician supervision, and emphasizing correct medication use are all good instincts. But the word "avoid" is doing a lot of heavy lifting here, and that's where things get complicated.

Does the science back this up?

Partially, yes. But "avoid" oversells what monitoring can actually do. The honest answer is that blood work reduces and helps detect risk early. It does not eliminate it.

On erythrocytosis (the "blood thickening" the creator mentions), this one is well-supported. Testosterone raises hematocrit, and regular CBC monitoring is the standard way to catch it before it becomes dangerous. Coviello et al. (2008, Journal of Clinical Endocrinology and Metabolism) confirmed elevated hematocrit is dose-dependent and manageable with dose adjustments or therapeutic phlebotomy.

On cardiovascular health, the picture is messier. The 2023 TRAVERSE trial (Lincoff et al., New England Journal of Medicine) showed testosterone therapy did not increase major adverse cardiac events in men with hypogonadism and elevated cardiovascular risk, which was genuinely reassuring. But it also found a higher rate of atrial fibrillation and pulmonary embolism in the testosterone group. Monitoring doesn't prevent arrhythmias. That's a meaningful gap in the creator's "monitor your way out of it" framing.

On infertility, testosterone suppresses the HPG axis and reduces sperm production. Monitoring testosterone levels does not protect fertility. This requires a completely different intervention, typically FSH and LH support via HCG or FSH analogs. Blood monitoring alone won't catch this problem in time if preserving fertility is the goal.

What did they get wrong (or right)?

They got the risk list mostly right. Erythrocytosis, thrombotic risk, cardiovascular effects, and infertility are the four most clinically relevant long-term concerns with TRT. That's a solid, honest list with no scare-mongering and no minimizing.

Where they missed: framing "proper" blood monitoring as the mechanism that lets you "avoid" all of these is inaccurate for at least two of the four. Infertility from testosterone-induced suppression of spermatogenesis requires active fertility preservation strategies, not just bloodwork. And certain cardiovascular risks, particularly atrial fibrillation flagged in TRAVERSE, are not reliably predicted or prevented by standard TRT labs.

The claim also implies that if something goes wrong, it was because monitoring wasn't done properly. That's not fair to patients. Some people develop polycythemia or clots even on carefully supervised TRT. Risk reduction is real. Risk elimination is not.

Credit where it's due: the emphasis on physician supervision and correct medication use is appropriate and often missing from TRT content that skews heavily toward bodybuilding culture. This creator acknowledged real risks without catastrophizing them, and that's genuinely useful.

What should you actually know?

If you're on TRT or considering it, here's what evidence actually supports.

• Regular CBC monitoring (every 3-6 months initially) is genuinely protective against hematocrit-related clotting risk. This one the creator got right.
• Fertility is a separate conversation. If you want to have children, talk to your doctor before starting TRT, not after. Testosterone shuts down sperm production, and standard lab panels won't warn you it's happening until it already has.
• Cardiovascular risk is not fully managed by bloodwork. The TRAVERSE trial (2023, NEJM) provided important reassurance on heart attack and stroke, but also showed higher rates of atrial fibrillation. Your doctor should know your full cardiac history before prescribing.
• "Blood thickening" and blood clots are related but not the same thing. High hematocrit increases viscosity and clotting risk. Monitoring hematocrit helps catch this. A personal or family history of clotting disorders requires a separate risk conversation.
• The phrase "if you do it properly" implies there's a version of TRT that is risk-free. There isn't. There's a version that's lower-risk and appropriately monitored, and that's meaningfully different.